Results 21 to 30 of about 413,379 (310)

Guillain-Barré Syndrome-related campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies [PDF]

open access: yes, 2012
BACKGROUND: <br/> Campylobacter jejuni is the predominant antecedent infection in Guillain-Barré syndrome (GBS). Molecular mimicry and cross-reactive immune responses to C.
Klaij, K   +82 more
core   +1 more source

Mucosal administration of anti-bacterial antibodies provide long-term cross-protection against Pseudomonas aeruginosa respiratory infection

open access: yes, 2023
International audienceBacterial respiratory infections either acute or chronic are major threats for human health. Direct mucosal administration, through the airways, of therapeutic antibodies (Ab) offers a tremendous opportunity to benefit to patients ...
Cortes, Mélanie   +17 more
core   +1 more source

Host Factors Determine Anti-GM1 Response Following Oral Challenge of Chickens with Guillain-Barre Syndrome Derived Campylobacter jejuni Strain GB11 [PDF]

open access: yes, 2010
Background: Anti-ganglioside antibodies with a pathogenic potential are present in C. jejuni-associated Guillain-Barre syndrome (GBS) patients and are probably induced by molecular mimicry.
Dijkstra, J.R. (Jeroen)   +50 more
core   +1 more source

Immunoglobulin for Treating Bacterial Infections: One More Mechanism of Action

open access: yesAntibodies, 2019
The mechanisms underlying the effects of immunoglobulins on bacterial infections are thought to involve bacterial cell lysis via complement activation, phagocytosis via bacterial opsonization, toxin neutralization, and antibody-dependent cell-mediated ...
Teiji Sawa   +4 more
doaj   +1 more source

New Role of Antibody in Bacterial Isolation

open access: yesJournal of AOAC INTERNATIONAL, 2012
Abstract To eliminate the interference caused by Pseudomonas aeruginosa in the isolation of Salmonella, a rabbit polyclonal antibody against P. aeruginosa was prepared by inoculating four New Zealand rabbits with the pathogen. The antiserum was purified using saturated ammonium sulfate and added into Rappaport-Vassiliadis medium with ...
Xizhi, Xiao   +9 more
openaire   +2 more sources

Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children

open access: yesExpert Review of Vaccines
Background Next-generation, higher-valency pneumococcal conjugate vaccines (PCVs), 15-valent PCV V114 and 20-valent PCV (PCV20), have been assessed by comparing their immune responses across serotypes shared with the 13-valent PCV (PCV13).
Josiah Ryman   +5 more
doaj   +1 more source

The Immunogenicity of Glutaraldehyde Inactivated PTx Is Determined by the Quantity of Neutralizing Epitopes

open access: yesVaccines
Background/Objectives: Chemically or genetically detoxified pertussis toxin (PTx) is a crucial antigen component of the acellular pertussis vaccine. Chemical detoxification using glutaraldehyde generally causes significant structural changes to the toxin.
Xi Wang   +5 more
doaj   +1 more source

IgY antibodies: The promising potential to overcome antibiotic resistance

open access: yesFrontiers in Immunology, 2023
Antibiotic resistant bacteria are a growing threat to global health security. Whilst the emergence of antimicrobial resistance (AMR) is a natural phenomenon, it is also driven by antibiotic exposure in health care, agriculture, and the environment ...
Sherif A. El-Kafrawy   +14 more
doaj   +1 more source

Epitope Mapping of Monoclonal and Polyclonal Antibodies Using Bacterial Cell Surface Display

open access: yes, 2014
The unique property of specific high-affinity binding to more or less any target of interest has made antibodies tremendously useful in numerous applications.
Rockberg, Johan,   +5 more
core   +1 more source

Monoclonal antibody-based therapies for bacterial infections [PDF]

open access: yesCurrent Opinion in Infectious Diseases, 2019
Purpose of review This review highlights recent developments in the development of monoclonal antibodies to treat bacterial disease, including preclinical advances and the status of current clinical trials. Recent findings Monoclonal antibody (mAb) therapy is becoming increasingly ...
Michael P, Motley   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy